REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:
Event: Guggenheim 3rd Annual Healthcare Innovation Conference Date: November 9-11, 2026 Fireside Date/Time: Monday, November 9th at 9:00am ET
Event: Jefferies London Healthcare Conference Date: November 16-19, 2026 Fireside Date/Time: Thursday, November 19th at 1:00pm GMT
Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim and Jefferies representatives.
About Rezolute, Inc.
Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.
Contacts:
Christen Baglaneas Rezolute, Inc. 1411 Broadway, 16th Floor New York, NY 10018 [email protected] 508-272-6717
Carrie McKim Rezolute, Inc. 1411 Broadway, 16th Floor New York, NY 10018 [email protected] 336-608-9706
